Thursday 5th October 2017
We are delighted to inform you that as part of our European growth strategy, ALS has completed the acquisition of Mikrolab Group on 3rd October 2017, which includes Mikrolab Stockholm AB, MKL Diagnostics AB and Toxicon AB.
Mikrolab and Toxicon provide a full range of services to the Pharmaceutical, Food and Environmental markets. The acquisition extends ALS's range of capabilities which will allow us to offer additional services to our clients in the future. ALS will also be able to offer the full network of services to the Mikrolab and Toxicon client base. The acquisition includes sites located in Stockholm and Landskrona.
The acquisition is an important part of ALS's plans to develop a significant global pharmaceutical business and further establishes ALS as a leading analytical testing service provider with extensive capabilties and unrivalled geographical coverage.
Commenting on the deal, Andreas Jonsson, General Manager Europe, "This exciting acquisition represents a step-change for the ALS Pharmaceutical business, providing a great opportunity to increase the depth and breadth of our client proposition.